Even at 0.5 mg, receptor activation begins and the body starts adapting to triple agonism
In clinical trials, both exenatide and lixisenatide reduced body weight by 2.03.8 kg and reduced HbA 1c levels by 0.51.5% (5.51.6 mmol/mol) [23,24,25]
In 2017-18 the timespan with the most recent data available about three-quarters of U.S
Pharmacokinetics (Coskun et al., Cell Metabolism 2022) Phase 1 PK data established the ~6-day half-life and once-weekly dosing rationale
In clinical trials, tirzepatide reduced sleep apnea events by as much as two-thirds or about 66% over the course of 52 weeks in patients with obstructive sleep apnea
When youre sleep deprived, research has shown that release of post-meal GLP-1 is delayed, which keeps you from feeling full when you should